Eli Lilly is expected to maintain its lead in the GLP-1 drug market for obesity and diabetes treatment, despite upcoming pill versions from competitors like Novo Nordisk. Analysts project Lilly's superior execution and strong market share in current injectable drugs, Mounjaro and Zepbound, will continue. While Novo Nordisk will launch the first GLP-1 pill, Lilly's anticipated pill and pipeline drugs like retatrutide are expected to drive sustained growth, solidifying its market dominance for years to come.